Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Penpulimab in Chemo-refractory mCRC
NCT04970914Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2021
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, penpulimab in metastatic colorectal cancer (mCRC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
anlotinibpenpulimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04970914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04970914.